Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121)

Studiedetails

Type carcinoma: NSCLC zonder mutatie
Stadium: IV
Mutatie: -
Lijn: 1e
Site: Erasmus MC & Amphia
Contactgegevens:

long.oncologie@erasmusmc.nl
researchlongoncologie@amphia.nl
Website:

 Inclusiecriteria

  • Stadium IV NSCLC, Squamous and non-squamous
  • Negative test results for (EGFR) and (ALK)
  • Have not received prior systemic treatment for metastatic NSCLC. Participants who received adjuvant or neoadjuvant chemotherapy are eligible if the adjuvant/neoadjuvant chemotherapy was completed at least 12 months prior to the start of study treatment.
  • One biopsies and fine needle aspirates are not suitable tissues
  • ECOG PS score 0 or 1

 Exclusiecriteria

Meer studies

Een overzicht van alle lopende studies binnen het longkankernetwerk. Filter op type mutatie:

KontRASt-06

An open-label Phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer (NSCLC) with a PD-L1 expression <1% or a PD-L1 expression ≥1% and an STK11 co-mutation